1
|
Nogueira CW, Barbosa NV, Rocha JBT. Toxicology and pharmacology of synthetic organoselenium compounds: an update. Arch Toxicol 2021; 95:1179-1226. [PMID: 33792762 PMCID: PMC8012418 DOI: 10.1007/s00204-021-03003-5] [Citation(s) in RCA: 109] [Impact Index Per Article: 36.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Accepted: 02/10/2021] [Indexed: 12/17/2022]
Abstract
Here, we addressed the pharmacology and toxicology of synthetic organoselenium compounds and some naturally occurring organoselenium amino acids. The use of selenium as a tool in organic synthesis and as a pharmacological agent goes back to the middle of the nineteenth and the beginning of the twentieth centuries. The rediscovery of ebselen and its investigation in clinical trials have motivated the search for new organoselenium molecules with pharmacological properties. Although ebselen and diselenides have some overlapping pharmacological properties, their molecular targets are not identical. However, they have similar anti-inflammatory and antioxidant activities, possibly, via activation of transcription factors, regulating the expression of antioxidant genes. In short, our knowledge about the pharmacological properties of simple organoselenium compounds is still elusive. However, contrary to our early expectations that they could imitate selenoproteins, organoselenium compounds seem to have non-specific modulatory activation of antioxidant pathways and specific inhibitory effects in some thiol-containing proteins. The thiol-oxidizing properties of organoselenium compounds are considered the molecular basis of their chronic toxicity; however, the acute use of organoselenium compounds as inhibitors of specific thiol-containing enzymes can be of therapeutic significance. In summary, the outcomes of the clinical trials of ebselen as a mimetic of lithium or as an inhibitor of SARS-CoV-2 proteases will be important to the field of organoselenium synthesis. The development of computational techniques that could predict rational modifications in the structure of organoselenium compounds to increase their specificity is required to construct a library of thiol-modifying agents with selectivity toward specific target proteins.
Collapse
Affiliation(s)
- Cristina W Nogueira
- Laboratório de Síntese, Reatividade e Avaliação Farmacológica E Toxicológica de Organocalcogênios, Centro de Ciências Naturais E Exatas, Universidade Federal de Santa Maria, Santa Maria, RS, CEP 97105-900, Brazil.
| | - Nilda V Barbosa
- Laboratório de Síntese, Reatividade e Avaliação Farmacológica E Toxicológica de Organocalcogênios, Centro de Ciências Naturais E Exatas, Universidade Federal de Santa Maria, Santa Maria, RS, CEP 97105-900, Brazil
| | - João B T Rocha
- Laboratório de Síntese, Reatividade e Avaliação Farmacológica E Toxicológica de Organocalcogênios, Centro de Ciências Naturais E Exatas, Universidade Federal de Santa Maria, Santa Maria, RS, CEP 97105-900, Brazil.
| |
Collapse
|
2
|
Sies H, Parnham MJ. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. Free Radic Biol Med 2020; 156:107-112. [PMID: 32598985 PMCID: PMC7319625 DOI: 10.1016/j.freeradbiomed.2020.06.032] [Citation(s) in RCA: 114] [Impact Index Per Article: 28.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 06/23/2020] [Accepted: 06/24/2020] [Indexed: 12/21/2022]
Abstract
Ebselen is an organoselenium compound exhibiting hydroperoxide- and peroxynitrite-reducing activity, acting as a glutathione peroxidase and peroxiredoxin enzyme mimetic. Ebselen reacts with a multitude of protein thiols, forming a selenosulfide bond, which results in pleiotropic effects of antiviral, antibacterial and anti-inflammatory nature. The main protease (Mpro) of the corona virus SARS-CoV-2 is a potential drug target, and a screen with over 10,000 compounds identified ebselen as a particularly promising inhibitor of Mpro (Jin, Z. et al. (2020) Nature 582, 289-293). We discuss here the reaction of ebselen with cysteine proteases, the role of ebselen in infections with viruses and with other microorganisms. We also discuss effects of ebselen in lung inflammation. In further research on the inhibition of Mpro in SARS-CoV-2, ebselen can serve as a promising lead compound, if the inhibitory effect is confirmed in intact cells in vivo. Independently of this action, potential beneficial effects of ebselen in COVID-19 are ascribed to a number of targets critical to pathogenesis, such as attenuation of inflammatory oxidants and cytokines.
Collapse
Affiliation(s)
- Helmut Sies
- Institute of Biochemistry and Molecular Biology I, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; Leibniz Research Institute for Environmental Medicine, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
| | - Michael J Parnham
- Faculty of Biochemistry, Chemistry and Pharmacy, JW Goethe University Frankfurt, Frankfurt am Main, Germany; Pharmacology Consultant, Bad Soden am Taunus, Germany.
| |
Collapse
|
3
|
The early research and development of ebselen. Biochem Pharmacol 2013; 86:1248-53. [DOI: 10.1016/j.bcp.2013.08.028] [Citation(s) in RCA: 147] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 08/21/2013] [Accepted: 08/23/2013] [Indexed: 11/22/2022]
|
4
|
Chew P, Yuen DY, Koh P, Stefanovic N, Febbraio MA, Kola I, Cooper ME, de Haan JB. Site-Specific Antiatherogenic Effect of the Antioxidant Ebselen in the Diabetic Apolipoprotein E–Deficient Mouse. Arterioscler Thromb Vasc Biol 2009; 29:823-30. [DOI: 10.1161/atvbaha.109.186619] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Phyllis Chew
- From the Oxidative Stress Group (P.C., N.S., J.B.d.H.), Diabetic Complications Group (P.K., M.E.C.), JDRF Diabetes and Metabolism Division, Cellular & Molecular Metabolism Laboratory (D.Y.C.Y., M.A.F.), Metabolism & Obesity Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; and the Schering-Plough Research Institute (I.K.), Schering-Plough Corporation, Kenilworth, NJ
| | - Derek Y.C. Yuen
- From the Oxidative Stress Group (P.C., N.S., J.B.d.H.), Diabetic Complications Group (P.K., M.E.C.), JDRF Diabetes and Metabolism Division, Cellular & Molecular Metabolism Laboratory (D.Y.C.Y., M.A.F.), Metabolism & Obesity Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; and the Schering-Plough Research Institute (I.K.), Schering-Plough Corporation, Kenilworth, NJ
| | - Philip Koh
- From the Oxidative Stress Group (P.C., N.S., J.B.d.H.), Diabetic Complications Group (P.K., M.E.C.), JDRF Diabetes and Metabolism Division, Cellular & Molecular Metabolism Laboratory (D.Y.C.Y., M.A.F.), Metabolism & Obesity Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; and the Schering-Plough Research Institute (I.K.), Schering-Plough Corporation, Kenilworth, NJ
| | - Nada Stefanovic
- From the Oxidative Stress Group (P.C., N.S., J.B.d.H.), Diabetic Complications Group (P.K., M.E.C.), JDRF Diabetes and Metabolism Division, Cellular & Molecular Metabolism Laboratory (D.Y.C.Y., M.A.F.), Metabolism & Obesity Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; and the Schering-Plough Research Institute (I.K.), Schering-Plough Corporation, Kenilworth, NJ
| | - Mark A. Febbraio
- From the Oxidative Stress Group (P.C., N.S., J.B.d.H.), Diabetic Complications Group (P.K., M.E.C.), JDRF Diabetes and Metabolism Division, Cellular & Molecular Metabolism Laboratory (D.Y.C.Y., M.A.F.), Metabolism & Obesity Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; and the Schering-Plough Research Institute (I.K.), Schering-Plough Corporation, Kenilworth, NJ
| | - Ismail Kola
- From the Oxidative Stress Group (P.C., N.S., J.B.d.H.), Diabetic Complications Group (P.K., M.E.C.), JDRF Diabetes and Metabolism Division, Cellular & Molecular Metabolism Laboratory (D.Y.C.Y., M.A.F.), Metabolism & Obesity Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; and the Schering-Plough Research Institute (I.K.), Schering-Plough Corporation, Kenilworth, NJ
| | - Mark E. Cooper
- From the Oxidative Stress Group (P.C., N.S., J.B.d.H.), Diabetic Complications Group (P.K., M.E.C.), JDRF Diabetes and Metabolism Division, Cellular & Molecular Metabolism Laboratory (D.Y.C.Y., M.A.F.), Metabolism & Obesity Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; and the Schering-Plough Research Institute (I.K.), Schering-Plough Corporation, Kenilworth, NJ
| | - Judy B. de Haan
- From the Oxidative Stress Group (P.C., N.S., J.B.d.H.), Diabetic Complications Group (P.K., M.E.C.), JDRF Diabetes and Metabolism Division, Cellular & Molecular Metabolism Laboratory (D.Y.C.Y., M.A.F.), Metabolism & Obesity Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; and the Schering-Plough Research Institute (I.K.), Schering-Plough Corporation, Kenilworth, NJ
| |
Collapse
|
5
|
Nogueira CW, Zeni G, Rocha JBT. Organoselenium and Organotellurium Compounds: Toxicology and Pharmacology. Chem Rev 2004; 104:6255-85. [PMID: 15584701 DOI: 10.1021/cr0406559] [Citation(s) in RCA: 1429] [Impact Index Per Article: 71.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Cristina W Nogueira
- Laboratório de Síntese, Reatividade e Avaliacão Farmacológica e Toxicológica de Organocalcogênios, CCNE, UFSM, Santa Maria, CEP 97105-900 Rio Grande do Sul, Brazil
| | | | | |
Collapse
|
6
|
Matsue H, Edelbaum D, Shalhevet D, Mizumoto N, Yang C, Mummert ME, Oeda J, Masayasu H, Takashima A. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2003; 171:3010-8. [PMID: 12960326 DOI: 10.4049/jimmunol.171.6.3010] [Citation(s) in RCA: 198] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Although reactive oxygen species (ROS) have long been considered to play pathogenic roles in various disorders, this classic view is now being challenged by the recent discovery of their physiological roles in cellular signaling. To determine the immunological consequence of pharmacological disruption of endogenous redox regulation, we used a selenium-containing antioxidant compound ebselen known to modulate both thioredoxin and glutaredoxin pathways. Ebselen at 5-20 micro M inhibited Con A-induced proliferation and cytokine production by the HDK-1 T cell line as well as the LPS-triggered cytokine production by XS52 dendritic cell (DC) line. Working with the in vitro-reconstituted Ag presentation system composed of bone marrow-derived DC, CD4(+) T cells purified from DO11.10 TCR-transgenic mice and OVA peptide (serving as Ag), we observed that 1) both T cells and DC elevate intracellular oxidation states upon Ag-specific interaction; 2) ebselen significantly inhibits ROS production in both populations; and 3) ebselen at 5-20 micro M inhibits DC-induced proliferation and cytokine production by T cells as well as T cell-induced cytokine production by DC. Thus, Ag-specific, bidirectional DC-T cell communication can be blocked by interfering with the redox regulation pathways. Allergic contact hypersensitivity responses in BALB/c mice to oxazolone, but not irritant contact hypersensitivity responses to croton oil, were suppressed significantly by postchallenge treatment with oral administrations of ebselen (100 mg/kg per day). These results provide both conceptual and technical frameworks for studying ROS-dependent regulation of DC-T cell communication during Ag presentation and for testing the potential utility of antioxidants for the treatment of immunological disease.
Collapse
Affiliation(s)
- Hiroyuki Matsue
- Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Ohta Y, Kobayashi T, Inui K, Yoshino J, Nakazawa S. Protective effect of ebselen, a seleno-organic compound, against the progression of acute gastric mucosal lesions induced by compound 48/80, a mast cell degranulator, in rats. JAPANESE JOURNAL OF PHARMACOLOGY 2002; 90:295-303. [PMID: 12501005 DOI: 10.1254/jjp.90.295] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The protective effect of ebselen, which possesses glutathione peroxidase-like activity and antioxidative and anti-inflammatory properties, against the progression of acute gastric mucosal lesions was examined in rats with a single intraperitoneal injection of compound 48/80 (0.75 mg/kg). Ebselen (50, 100 or 200 mg/kg) was orally administered 0.5 h after compound 48/80 treatment, at which time gastric mucosal lesions appeared. Post-administered ebselen suppressed gastric mucosal lesion progression at 3 h after compound 48/80 treatment dose-dependently, although no dose of ebselen affected the decreased gastric mucosal blood flow and increased serum serotonin and histamine concentrations found at 3 h after the treatment. A decrease in Se-glutathione peroxidase activity and increases in myeloperoxidase and xanthine oxidase activities and the concentration of thiobarbituric acid reactive substances were found in gastric mucosal tissues at 0.5 h after compound 48/80 treatment, and these changes were further enhanced at 3 h. Post-administered ebselen attenuated all these changes found at 3 h after compound 48/80 treatment dose-dependently. The present results indicate that ebselen exerts a protective effect against the progression of compound 48/80-induced acute gastric mucosal lesions in rats, and they suggest that this protective effect of ebselen could be due to its glutathione peroxidase-like activity and its antioxidative and anti-inflammatory properties.
Collapse
Affiliation(s)
- Yoshiji Ohta
- Department of Chemistry, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.
| | | | | | | | | |
Collapse
|
8
|
Imai H, Masayasu H, Dewar D, Graham DI, Macrae IM. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke 2001; 32:2149-54. [PMID: 11546910 DOI: 10.1161/hs0901.095725] [Citation(s) in RCA: 147] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE The neuroprotective efficacy of an intravenous formulation of the antioxidant ebselen has been comprehensively assessed with specific regard to conventional quantitative histopathology, subcortical axonal damage, neurological deficit, and principal mechanism of action. METHODS Transient focal ischemia (2 hours of intraluminal thread-induced ischemia with 22 hours of reperfusion) was induced in the rat. Ebselen (1 mg/kg bolus plus 1 mg/kg per hour IV) or vehicle was administered at the start of reperfusion and continued to 24 hours. Neurological deficit was assessed 24 hours after ischemia. Gray matter damage was evaluated by quantitative histopathology. Axonal damage was determined with amyloid precursor protein immunohistochemistry used as a marker of disrupted axonal flow and Tau-1 immunohistochemistry to identify oligodendrocyte pathology. Oxidative damage was determined by 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 4-hydroxynonenal (4-HNE) immunohistochemistry. RESULTS Ebselen significantly reduced the volume of gray matter damage in the cerebral hemisphere (by 53.6% compared with vehicle, P<0.02). Axonal damage was reduced by 46.8% (P<0.002) and the volume of oligodendrocyte pathology was reduced by 60.9% (P<0.005). The neurological deficit score was reduced by 40.7% (P<0.05) and the volume of tissue immunopositive for 8-OHdG and 4-HNE was reduced by 65% (P<0.002) and 66% (P<0.001), respectively, in ebselen-treated animals. CONCLUSIONS Delayed (2-hour) treatment with intravenous ebselen significantly reduced gray and white matter damage and neurological deficit associated with transient ischemia. The reduction in tissue displaying evidence of oxidative stress suggests that the major mechanism of action is attenuation of free radical damage.
Collapse
Affiliation(s)
- H Imai
- Wellcome Surgical Institute and Department of Neuropathology, University of Glasgow, Glasgow, Scotland
| | | | | | | | | |
Collapse
|
9
|
Kobayashi T, Ohta Y, Yoshino J. Preventive effect of ebselen on acute gastric mucosal lesion development in rats treated with compound 48/80. Eur J Pharmacol 2001; 414:271-9. [PMID: 11239928 DOI: 10.1016/s0014-2999(01)00815-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The preventive effect of ebselen, a seleno-organic compound, which is known to possess glutathione peroxidase-like activity and antioxidative and anti-inflammatory properties, on the development of acute gastric mucosal lesions was examined in rats with a single injection of compound 48/80 (0.75 mg/kg, i.p.), a mast cell degranulator. Pre-administration of ebselen (p.o.) at a dose of 50 or 100 mg/kg, but not 10 mg/kg, prevented gastric mucosal lesion development at 3 h, but not gastric mucosal lesion formation at 0.5 h, after compound 48/80 injection, although any dose of pre-administered ebselen did not affect decreased gastric mucosal blood flow and increased serum serotonin and histamine concentrations found at 0.5 and 3 h after compound 48/80 injection. A decrease in Se-glutathione peroxidase activity and increases in the activities of myeloperoxidase, an index of tissue neutrophil infiltration, and xanthine oxidase and the concentration of thiobarbituric acid reactive substances, an index of lipid peroxidation, were found in gastric mucosal tissues at 0.5 h after compound 48/80 injection and these changes were further enhanced at 3 h. Pre-administration of ebselen (p.o.) at a dose of 50 or 100 mg/kg, but not 10 mg/kg, attenuated all these changes found at 3 h after compound 48/80 injection. These preventive effects of ebselen occurred in a dose-dependent manner. The present results indicate that pre-administered ebselen prevents the development of compound 48/80-induced acute gastric mucosal lesions in rats, and suggest that this preventive effect of ebselen could be due to its glutathione peroxidase-like activity and antioxidative and anti-inflammatory properties.
Collapse
Affiliation(s)
- T Kobayashi
- Department of Internal Medicine, Second Teaching Hospital, School of Medicine, Fujita Health University, Otobashi, Nakagawa-ku, Aichi 454-0012, Nagoya, Japan
| | | | | |
Collapse
|
10
|
Walther M, Holzhütter HG, Kuban RJ, Wiesner R, Rathmann J, Kühn H. The inhibition of mammalian 15-lipoxygenases by the anti-inflammatory drug ebselen: dual-type mechanism involving covalent linkage and alteration of the iron ligand sphere. Mol Pharmacol 1999; 56:196-203. [PMID: 10385701 DOI: 10.1124/mol.56.1.196] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Mammalian lipoxygenases have been implicated in inflammation and atherosclerosis and, thus, lipoxygenase inhibitors may be of pharmacological interest. In cells, lipoxygenases occur in a catalytically silent ground state that requires activation to become active. We found that the seleno-organic drug ebselen [2-phenyl-1, 2-benzisoselenazol-3(2H)-one], which exhibits anti-inflammatory properties, irreversibly inhibited pure rabbit 15-lipoxygenase, with an IC50 in the nM range when preincubated with the enzyme in the absence of fatty acid substrates. Subsequent dialysis, gel filtration, or substrate addition did not restore the enzyme activity, and experiments with [14C]ebselen indicated a covalent linkage of the drug. The presence of sulfhydryl compounds in the incubation mixture prevented both enzyme labeling and inactivation, but we did not see any reactivation when sulfhydryl compounds were added afterward. X-ray absorption studies indicated that ebselen did alter the geometry of the iron ligand sphere, and the data are consistent with an iron complexation by the drug. When fatty acid substrate was present during lipoxygenase-ebselen interaction, the inhibitory potency was strongly reduced and a competitive mode of action was observed. These data suggest that ebselen inactivated the catalytically silent ground-state lipoxygenase irreversibly by covalent linkage and alteration of the iron ligand sphere. In contrast, it functions as a competitive inhibitor of the catalytically active enzyme species. The pharmacological relevance of ebselen as a potential in vivo lipoxygenase inhibitor will be discussed.
Collapse
Affiliation(s)
- M Walther
- Institute of Biochemistry, University Clinics Charité, Humboldt University, Berlin, Germany
| | | | | | | | | | | |
Collapse
|
11
|
Knollema S, Elting J, Dijkhuizen R, Nicolay K, Korf J, Ter Horst G. Ebselen (PZ-51) protects the caudate putamen against hypoxia/ischemia induced neuronal damage. ACTA ACUST UNITED AC 1999. [DOI: 10.1002/(sici)1520-6769(199607)19:1<47::aid-nrc162>3.0.co;2-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
12
|
Takasago T, Peters EE, Graham DI, Masayasu H, Macrae IM. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br J Pharmacol 1997; 122:1251-6. [PMID: 9401794 PMCID: PMC1565026 DOI: 10.1038/sj.bjp.0701426] [Citation(s) in RCA: 128] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
1. The aim of this study was to investigate whether delayed treatment with the anti-oxidant and anti-inflammatory agent ebselen reduces the volume of infarction in a rodent model of permanent focal cerebral ischaemia. 2. Ebselen (10 or 30 mg kg-1) or vehicle was administered by gavage 30 min and 12 h after the induction of cerebral ischaemia by permanent occlusion of the left middle cerebral artery (MCA). Animals were killed 24 h following MCA occlusion, and the volumes of ischaemic damage in the ebselen and control groups were evaluated by quantitative histopathology. 3. Ebselen was quickly absorbed following oral (gavage) administration and reached peak levels in the plasma by 1 h post-administration (plasma selenium level of 0.68 +/- 0.04 and 0.84 +/- 0.1 microgram ml-1 for 10 and 30 mg kg-1, respectively, compared to control level of 0.51 +/- 0.02 microgram kg-1). 4. Treatment with the lower dose of ebselen (10 mg kg-1) significantly (P < 0.01) reduced the volume of infarction in the cerebral hemisphere and cerebral cortex (by 31.8% and 36.7%, respectively compared with the placebo group). 5. The neuroprotective efficacy of the higher dose ebselen (30 mg kg-1) was less than that of the lower dose ebselen (10 mg kg-1). The volume of ischaemic damage in the cerebral hemisphere was reduced by 23.7% (P < 0.02), and cerebral cortex by 27.5% (P < 0.01). 6. Both doses of ebselen (10, 30 mg kg-1) had no therapeutic efficacy on the caudate nucleus, where ischaemia was most severe, in this model. 7. Free radical-mediated injury is normally associated with reperfusion of ischaemic tissue. The present results suggest that oxidative injury is also a significant contributor to brain damage in models of maintained (permanent) ischaemia and that ebselen is effective in attenuating this free radical-induced damage.
Collapse
Affiliation(s)
- T Takasago
- Wellcome Surgical Institute & Hugh Fraser Neuroscience Labs., University of Glasgow
| | | | | | | | | |
Collapse
|
13
|
Abstract
1. Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) is a non-toxic seleno-organic drug with antiinflammatory, antiatherosclerotic and cytoprotective properties. 2. Ebselen and some of its metabolites are effective reductants of hydroperoxides including those arising in biomembranes and lipoproteins. 3. By reactions with hydroperoxides and thiols several interconversion cycles are formed which include ebselen metabolites with varying oxidation number of the selenium. 4. In the presence of thiols ebselen mimics the catalytic activities of phospholipid hydroperoxide glutathione peroxidase. 5. Ebselen inhibits at low concentrations a number of enzymes involved in inflammation such as lipoxygenases, NO synthases, NADPH, oxidase, protein kinase C and H+/K(+)-ATPase. The inhibitions are manifested on the cellular level and may contribute to the antiinflammatory potential of ebselen.
Collapse
Affiliation(s)
- T Schewe
- Institute of Biochemistry, University Clinics Charité, Humboldt University of Berlin, Germany
| |
Collapse
|
14
|
Cury Y, Teixeira CF, Sudo LS. Edematogenic responses induced by Bothrops jararaca venom in rats: role of lymphocytes. Toxicon 1994; 32:1425-31. [PMID: 7886700 DOI: 10.1016/0041-0101(94)90414-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The intraplantar injection of Bothrops jararaca venom (Bjv) caused an edematogenic response in the rat which was of rapid onset, and reached a peak in about 60 min. The response was markedly attenuated in animals rendered leucopenic by the administration of amethopterin. This inhibition was partially reverted when leucopenic rats were given i.v. suspensions of lymphocytes. Suspensions of neutrophils were ineffective. If the animals were submitted to an experimental obstruction of the thoracic duct, which leads to specific lymphocytopenia, similar inhibition of the edematogenic response was observed. These results suggest that lymphocytes can directly influence the development of the edema induced by Bothrops jararaca venom.
Collapse
Affiliation(s)
- Y Cury
- Laboratory of Pathophysiology, Butantan Institute, São Paulo, Brazil
| | | | | |
Collapse
|
15
|
Gao JX, Issekutz AC. The effect of ebselen on T-lymphocyte migration to arthritic joints and dermal inflammatory reactions in the rat. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1994; 16:279-87. [PMID: 8045667 DOI: 10.1016/0192-0561(94)90002-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We have previously observed that ebselen (PZ 51, 2-Phenyl-1,2-Bensoisoselenazol-3-(2H)-one) can inhibit human polymorphonuclear leukocyte (PMNL) transendothelial migration in vitro and PMNL migration to arthritic joints and dermal inflammatory reactions in rats. In this study, we investigated the effect of ebselen on T-lymphocyte migration to the inflamed joints in rats with adjuvant arthritis (AA) and to dermal inflammation induced by cytokines (IFN gamma, mTNF alpha), cytokine inducing stimuli (poly I:C and LPS), or a delayed type hypersensitivity (DTH) reaction. Treatment of rats with AA with ebselen (100 mg/kg/day) p.o. for three days significantly reduced accumulation of 111In-labelled spleen T-cells (SPLT) in the arthritic joints, including forepaws, carpal joints, hindpaws and talar joints, and in all the above dermal inflammatory reactions. The inhibitory effect of ebselen on SPLT cell accumulation was greater than with indomethacin (2 mg/kg/day) and was observed within 3 h of initiation of ebselen treatment. Ebselen also inhibited SPLT migration to mandibular, axillary and mesenteric lymph nodes, and to the spleen. The results suggest that not only does ebselen inhibit SPLT migration to inflamed joints and to dermal inflammation but it also may inhibit lymphocyte homing and recirculation. Whether these effects of ebselen are related to its reported inhibition of cellular activation and intracellular signalling requires further investigation. However, the inhibition of T-lymphocyte migration reported here and of PMNL migration reported previously may both be beneficial in the treatment of human arthritis.
Collapse
Affiliation(s)
- J X Gao
- Department of Pediatrics and Microbiology-Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
| | | |
Collapse
|